Takeda Report Submission of NDA to MHLW for Cabometyx (cabozantinib) to Treat Advanced Hepatocellular Carcinoma in Japan

 Takeda Report Submission of NDA to MHLW for Cabometyx (cabozantinib) to Treat Advanced Hepatocellular Carcinoma in Japan

Takeda Report Submission of NDA to MHLW for Cabometyx (cabozantinib) to Treat Advanced Hepatocellular Carcinoma in Japan

Shots:

  • The NDA is based on two clinical studies, P-III CELESTIAL (XL184-309) & P-II Cabozantinib-2003 study assessing Cabometyx in patients with advanced HCC prior treated with systemic therapy
  • In 2017, Exelixis and Takeda collaborated for Cabometyx in Japan, under which Exelixis will receive ~$10M milestones following the NDA submission for HCC, expected to receive in Q1’20. Additionally, Exelixis will receive ~$76M as development, regulatory and first-sale milestones for regulatory filing in previously untreated & treated RCC & HCC respectively
  • Takeda provides funds for the development of therapy in Japan and is responsible for 20% of the global development cost of the therapy. Cabometyx is an approved therapy for patients with HCC prior treated with sorafenib

Click here ­to­ read full press release/ article | Ref: Exelixis | Image: Takeda

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post